Bioproduction of proteins
The PPP Unit counts with a laboratory perfectly equipped for the bioproduction of recombinant proteins. The expression system is selected according to the protein characteristics and customer’s needs.
Transformation/transfection: the engineered construct is introduced inside the chosen expressing cells. In certain instances, involving insect expression, this step includes the isolation of a bacmid made for protein production via the baculovirus system.
Optimisation: selection of the optimal protein production conditions using small and medium-scale expression; confirmation of the protein expression using SDS-PAGE and Western blot analysis and quantification by densitometry. At this step protein solubility/aggregation is measured to obtain the best solubilizing conditions.
Recombinant protein production: scale-up of the upstream processing by batch culture according to the best protein production conditions selected during the optimization step.
Customer benefits
The service is completely personalised to ensure that the protein matches the intended use for later protein purification. Thus, instead of offering a generic solution, we deliver a customised product with the exact specifications and needs requested by the customer.
We have various expression systems to address specific needs, offering a wide range of possibilities for obtaining the final product. All services adhere to standardised procedures, guaranteeing the quality of the end product.
Target customer
The PPP Unit extends its services across the scientific community, serving both private and public research organizations. This includes support for research centres, universities, hospitals, and companies in the sector. Leveraging our connection with the university, the PPP unit also provides specialised courses as part of the official master’s degrees and PhD programs at UAB.
Additional information
Over its 17-year history, the PPP unit has successfully completed over 400 projects and has been recognised in more than 121 scientific publications. In the past three years, it has received citations in the following works:
- ACS Materials Lett. 2024, 6, 3, 954–962
- Front. Immunol. 2024. 15:1346512.
- Applied Microbiology and Biotechnology (2024) 108:98
- ACS Sustainable Chem. Eng. 2023, 11, 4133−4144
- Pharmaceutics 2023, 15, 2632.
- Microbial Cell Factories (2023) 22:81
- Biomed Pharmacother 2023. 164:114976.
- ACS Appl. Mater. Interfaces 2023, 15, 39167−39175
- Pharmaceutics 2023, 15, 1197
- Sci China Mater 2023, 66(10): 4109–4120
- Pharmaceutics 2023, 15(3), 727
- Biomedicine & Pharmacotherapy 2023, 169(1):115848
- Appl Environ Microbiol 2023 Jun 28;89(6)
- Biomedicine & Pharmacotherapy 150 (2022) 112940
- Biomaterials 280 (2022) 121258
- Pharmaceutics 2022, 14, 887
- J. Exp Clin Cancer Res (2022) 41:49
- DRUG DELIVERY 2022, VOL. 29, NO. 1, 1384–1397
- Biomedicines 2022, 10, 1680.
- Microbial Cell Factories (2022) 21:203
- Acta Pharmaceutica Sinica B 2022;12(5):2578e2591
- Pharmaceutics 2022, 14, 602.
- Pharmaceutics 2022, 14, 192.
- Front. Bioeng. Biotechnol. 2022 10:842256.
- Anal. Chem. 2022, 94, 5359−5366
- Odontology (2022) 110:545–556